Clinical trials: Phenytoin Toxicity
Pancreatic Cancer
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy.
- Trial name
- NCT03512756
- Testing
- SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
- Where
- 20 sites in United States
- Volunteers
- 130 people
- Sponsor
- Tyme, Inc